Clinical trials
Primary Myelofibrosis trials in Hong Kong
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
11 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Unknown status | 3 |
| Completed | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The University of Hong Kong | 4 |
| Novartis Pharmaceuticals | 2 |
| Celgene | 1 |
| Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 1 |
| Kartos Therapeutics, Inc. | 1 |
| Merck Sharp & Dohme LLC | 1 |
| PharmaEssentia | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Primary Myelofibrosis | 11 |
| Myeloproliferative Disorders | 3 |
| Thrombocythemia, Essential | 3 |
| Polycythemia Vera | 2 |
| Anemia | 1 |
Trials
Showing 1 to 11 of 11. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.